REFERENCIAS BIBLIOGRÁFICAS I. Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibro-blast cyclooxigenase expression and transcriptional and translational phases. Proc NatlAcad Sci USA 1989;86:1657-1661. 2. Crofford Leslie, Lipsky P, Brooks P, et al. Basic biology and clinical application of specific cyclooxigenase-2- inhibitors. Arthritis Rheum 2000; 43:1-14. 3. Cryer B, Feldman M. Cyclooxygenase-I and cyclooxigenase-2 selectivity of widely used nonsteroidal and inflammatory drugs Am J Med 1998;104: 413-21. 4. Selective COX2 Inhibitor Pharmacology, Clinical effect and therapeutical potential. Ed Vane John, pag 8. 1997. 5. Kurumbail R, Stevens A, Gierse J, et al.Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents. Nature 1996; 384: al bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343:769-72. 9. MacDonald, T Morant S, Robinson G, et al. Association of upper gastrointestinal toxicity of non-steroidal antiinflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-7. 10. Hawkey C, Laine I, Simon T, et al. Comparison of effect of rofecoxib (a cyclooxy-genase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis.Arthritis Rheum 2000;43: 370-377. 11. Lefkowith JB. Especificidad a cyccooxxgenasa-2 y sus implicancias clínicas. Am J Med 1999: 106 (58): 43S-50S. 12. Simon L, Weaver A, Graham D, et al.Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial ]AMA 1999; 282:192 1-8. 13. Singh G. Recent Considerations in nonsteroidal antiinflammatory drug gastropathy. Am J Med 1998; 105(IB):31S-38S. 14. Silverstein F, Graham D, Señor JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal and inflammatory drugs: A randomized, double blind, placebo controlled trial. Ann Intern Med 1995, 123:241-249. 15. Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 2000; 284: 1247-55 16. Goldstein J, Eisen G, Stenson W et al. Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDS. The SUCCESS I Trial. Scientific Abstracts, EULAR Congress,June 2001 17. Singh G, Goldstein N,Agrawal G, et al. COX-2 specific inhibitors-is there any benefit of using these agents in patients on low dose aspirin (ASA)?. Scientific Abstracts, EULAR Congress, June 2001 18. Langman M, Jensen D Watson D, et al.Adverse Upper Gastrointestinal Effects of rofecoxib compared with NSAIDs.JAMA 1999; 282: 1929-33 19. Bombardier C, Laine L Reicin L, et al . Comparison of the upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520-8. 20. Schoenfeld P Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trial.Am J Med 1999; 107:48S- 54S 21. FitzGerald G, Patrono C. The Coxibs, Selective Inhibitor of Cyclooxygenase-2. N EnglJ Med 2001; 345:433-442 22. Guidance on the use of cyclooxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and reumathoid arthritis. National Institute for Clinical Excellence.July 2001. 23. Simon L, Weaver A, Graham D,et al.Anti-inflammatory and uppergastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. )AMA 1999-,282:192 1-8 24. Geis S, Stead H, Morant S, et al Efficacy and safety of celecoxib,a specific COX-2 inhibitor, in patients rheumatoid arthritis MeetingACR 1998. 25.Bensen W, Fietchner j, McMillen J, et al. Treatment in osteoarthritis with celecoxib, a cyclooxigenase-2 inhibitor: A controlled and randomized clinical trial. Mayo Clin Proc 1999;74:1095-1105. 26. Day R, Morrison B, Luza A,et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs. ibuprofen in patients with osteoarthritis.Arch Intern Med 2000;160:1781-1787. 27. Cannon G, Caldwell J, Holt P, et al. Rofecoxib , a specific of cyclooxigenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000; 43(5):978-987. 28. Schwartz J, Agrawal P Wong K, et al. No effect of rofecoxib up to 50 mg daily on methotrexate plasma concentration. Annals of the Rheumatic Diseases 2000; 59: 150. 29. Truitt, Schnitzer T, Fleischmann, Seidenberg E, et al. A two part placebo and active comparator-controlled study of rofecoxib in the treatment of rheumatoid ar-thritis: one-year experience. Annals of the Rheumatic Diseases 2000; 59: 165. 30. Bertin P, Behier J, Noel E et al. Efficacy of celecoxib in patients with acute shoulder pain. Randomized double blind comparison with naproxen. Scientific Abstracts, EULAR Congress,June 2001. 31. Katz N. Rofecoxib in the treatment of the chronic low back pain. Meeting American Pain SocietyApril 2001. 32. SchnitzerT, Kivitz, Greenwald M, et al. Rofecoxib provides superior relief of symptoms of osteoarthritis compared to celecoxib, Scientific Abstracts, EULAR Congress,June 2001. 33. Gotzche P Non-steroidal anti-inflammatory drugs. In Clinical Evidence BMJ Publishing Group 2000. Pag 641-647, London UK. 34. Brooks P. Non-steroidalanti-inflammatory drug. In Rheumatology.Ed:KlippelJ, Dieppe P Mosby International 1998 Chap 3 pag 5.1-5.6 London UK. 35. Walker J, Sheather-Reid R, Carmody JET Nonsteroidal and inflammatory drugs in rheumatoid arthritis and osteoarthritis . Support for the concept "responders and "non responders". Arthritis Rheum 1997 40:1944-1954. 36. WheltonA.Nephrotoxicity of non steroidal anti-inflammatory drugs: Physiologic foundation and clinical implications. Am J Med 1999; 106(58): 13S-24S. 37. Swan S, Rudy D, et al. Effect of cyclooxigenase -2 inhibition on renal function in elderly persons receiving a low salt diet Ann Intern Med 2000; 133:1-9. 38 Whelton A. The Celecoxib long term safety study (CLASS): Celecoxib is associated with less renal toxicity compared to conventional nonsteroidal anti-inflammatory drugs. Scientific Abstracts, EULAR Congress,June 2001. 39. Whelton A, Singh W White W et al Celecoxib does not increase risk of cardiac failure, edema or hypertension compared to NSAIDS: results from SUCCESS I in 13,274 OA patients. Scientific Abstracts, EULAR Congress, June 2001. 40. Whelton A, Schulman G, Wallemark C, et al Effect of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000; 160: 1465-1470 . 41. Geba G, Polis A, Dixon M, et al. Comparative blood pressure effects of rofecoxib, celecoxib and placebo in patients with osteoarthritis (OA):A randomized controlled trial. Scientific Abstracts, EULAR Congress, June 2001. 42. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundation and clinical implications. Am J Med 1999; 106(58): 13S-24S. 43. Van Hecken A, Schwartz J, Depre M et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-I en healthy volunteers,) Clin Pharmacol 2000; 40:1109-20. 44. Brochier M. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty acute myocardial infarction. Europ Heart) 1993; 14:951-7. 45. Geba G, Lisse J, Perlman M, et al. Gastrointestinal tolerability in primary care patients treated with naproxen or rofecoxib for osteoarthritis:The ADVAN-TAGE trial. Scientific Abstracts, EULAR Congress, June 2001. 46. Shapiro D. Barr E, Reicin A. Cardiovascular safety of rofecoxib:A meta-analysis. Scientific Abstracts, EULAR Congress, June 200 I . 47. Leese P, Recker D , Kuss M.A double blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel cox-2 specific inhibitor on platelet function in the elderly. Scientific Abstracts, EULAR Congress,June 2001. 48, Schnitzer T, Geusens P, Hasler P, et al. Efficacy and safety of COX 189 in osteoarthritis:A multinational study ScientificAbstracts.ACR 64 Annual Meeting 2000. 49. Rindeau D, Percival D, Brideau C, et al.Etoricoxib(MK-0663):Preclinicalprofile and comparison with other agents that selectively inhibit cyclooxygenase -2.J Pharmacol ExperimTherap 2001; 296: 558-66. 50. Curtis S, Fisher C, Kafka S, et al. Treatment with etoricoxib(MK-0663),ACOX-2 selective inhibitor, resulted in clinical improvement in knee osteoarthritis (OA) over 52 weeks. Scientific Abstracts, EULAR Congress,June 2001. 51. Curtis S, Maldonado Cocco J, Losada B, et al.Treatment with etoricoxib (MK-0663),A COX-2 selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis. Scientific Abstracts, EULAR Congress,June 2001. |